News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
3
AI in Action: Breaking Down Clinical Trial Bottlenecks
4
Unlocking the Potential of Agentic AI to Reduce Trial Delays
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
